Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: Relationship with levels of circulating CEA

British Journal of Cancer

Volumn 81, Issue 1, 1999, Pages 19-23

  Watson, S A ^a   Morris, T M ^a   Collins, H M ^a   Bawden, L J ^b   Hawkins, K ^b   Bone, E A ^b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Gastric carcinoma; Marimastat; Matrix metalloproteinases; Tumour antigens

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; STOMACH CANCER; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; CELL DIVISION; ENZYME INHIBITORS; FEMALE; GROWTH INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; METALLOENDOPEPTIDASES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; STOMACH NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032834472     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690645     Document Type: Article

References (32)

1. Allen-Mersh TG, Kemeny N, Niedzwiecki D, Shurgot B and Daly JM (1987) Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut 28: 1625-1629
2. Anderson IC, Shipp MA, Docherty AJP and Teicher BA (1996) Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastases of murine Lewis lung carcinoma. Cancer Res 56: 715-718
3. Chirivi RG, Garolafo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD and Giavazzi R (1994) Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58: 460-464
4. Cotlam DW and Rees RC (1993) Regulation of matrix metalloproteinases: their role in tumour invasion and metastasis, Int J Oncol 2: 861-872
5. Davies B, Brown PD, East N, Crimmin MJ and Balkwill FR (1993) A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts, Cancer Res 53: 2087-2091
6. D'Enico A, Garbisa S, Liotta LA, Castronovo V, Stetler-Stevenson WG and Grigioni WF (1991) Augmentation of type IV collagenase, Iaminin receptor, and Ki67 proliferation antigen associated with human colon, gastric and breast carcinoma progression. Modern Pathol 4: 239-246
7. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W and Brown PD (1996) Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56: 2815-2822
8. Giavazzi R, Garofalo A, Ferri A, Lucchini V, Bone EA, Chiari S, Brown PD, Nicoletti MI and Taraboletti G (1998) Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumour activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 4: 985-992
9. Goldenberg DM, Neville AM, Carter AC, Go VL, Holyoke ED, Isselbacher ED, Schein PS and Schwartz M (1981 ) CEA (carcinoembryonic antigen): its role as a marker in the management of cancer. J Cancer Res Clin Oncol 101: 239-242
10. Gore M, A'llern R, Stankiewicz M and Slevin M (1996) Tumour marker levels during marimastat therapy. Lancet 348: 263
11. Hida J, Yasutomi M, Shindoh K, Kitaoka M, Fujimoto K, Ieda S, Machidera N, Kubo K, Morikawa E, Inufusa H, Watatani M and Okuno K (1996) Sceond-look operation for recurrent colorectal cancer based on carcinoembryonic antigen and imaging techniques. Dis Colon Rectum 39: 74-79
12. Hine KR and Dykes PW (1984) Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA. Gut 25: 682-68
13. Hojo J (1977) Establishment of cultured cell lines of human stomach cancer origin and their morphological characteristics. Niigata Igakukai Zasshi 91: 737
14. Honda M, Mori M, Ueo H, Sugimachi K and Akiyoshi T (1996) Matrix metalloproteinase-7 expression in gastric carcinoma. Gut 39: 444-448
15. Kleiner DE Jr and Steller-Stevenson WG (1993) Structural biochemistry and activation of matrix metalloproteinases. Curr Opin Cell Biol 5: 891-897
16. Liotta LA and Stetler-Stevenson WG (1990) Metalloproteinases and cancer invasion Sem Cancer Biol 1: 99-106
17. Matrisian LM (1992) The matrix-degrading metalloproteinases. Bioessays 14: 455-463
18. McDonnell S, Navre M, Coffey RJ and Matrisian LM (1991) Expression and localisation of the matrix metalloproteinase Pump-1 (MMP-7) in human gastric and colon carcinoma. Molecular Carcinogenesis 4: 527-533
19. Millar A and Brown PD (1996) 360 patient meta-analysis of studies of marimastat, a novel matrix metalloproteinase inhibitor. Ann Oncol 7: 123
20. Millar A, Brown P, Cornish A and Baillet M (1996) Tumour marker levels during marimastat therapy: reply. Lancet 348: 263-264
21. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D. Cox D and Millar A (1998) Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastal on serum tumour markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4: 1101-1109
22. NIH Consensus Statement (1981) Carcinoembryonic antigen: its role as a marker in the management of cancer. Br Med J 282: 373-375
23. Pimm MV, Robins RA and Baldwin RW (1992) Capture of recombinant ricin A chain by a bispecific anti RTA: anti-CEA monoclonal antibody pre-targeted to a human gastric carcinoma xenograft in nude mice. J Cancer Res and Clin Oncol 118: 367-370
24. Primrose JN, Bleiberg H, Daniel F, Van Belle S, Mansi JL, Seymour M, Johnson PW, Neoptolomos JP, Baillet M, Barker K, Berrington A, Brown PD, Millar AW and Lynch KP (1999) Pilot study of oral marimastat in recurrent colorectal cancer: an evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer 79: 509-514
25. Sledge GW Jr, Qulali M, Goulet R, Bone EA and Fife R (1995) Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87: 1546-1550
26. Stetler-Stevenson WG, Hewitt R and Corcoran M (1996) Matrix metalloproteinases and tumour invasion: from correlation and causality to the clinic. Semin Cancer Biol 7: 147-154
27. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD and Giavazzi R (1995) Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87: 293-298
28. Wang X, Fu X, Brown PD, Crimmin MJ and Hoffman RM (1994) Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54: 4726-4728
29. Ward U, Primrose JN, Finan PJ, Perren TJ, Selby P, Purves DA and Cooper EH (1993) The use of tumour markers CEA, CA-129 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 67: 1132-1135
30. 2 prostaglandin enprostil, and the somatostatin analogue SMS 201 995, in the growth of a human gastric cell line, MKN45G. Int J Cancer 45: 90-94
31. Watson SA, Durrant LG, Wencyk PM, Watson AL and Morris DL (1991) Intracellular gastrin in human gastrointestinal tumor cells. J Natl Cancer Inst 83: 866-871
32. Watson SA, Morris TM, Robinson G, Crimmin MJ, Broun PD and Hardcastle JD (1995) Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 55: 3629-3633